Katayama A et al., 2026-03-08: Retrospective cohort of 415 living-donor liver transplant patients in which pre-reperfusion methylene blue was associated with less stage 1 acute kidney injury and less early allograft dysfunction.
MB just prior to graft reperfusion was associated with decreased incidence of postoperative AKI stage 1 in LDLT.
Katayama A et al., 2026-03-08: Retrospective cohort of 415 living-donor liver transplant patients in which pre-reperfusion methylene blue was associated with less stage 1 acute kidney injury and less early allograft dysfunction. C10 (renal, human observational). Study type: retrospective cohort, N=415, living-donor liver transplantation January 2018 – June 2023; Department of Anesthesiology and Perioperative Medicine (country not stated in the abstract; authors' institution per journal listing). Dose: methylene blue given just before graft reperfusion; the abstract does not give mg/kg. Comparator: patients not receiving methylene blue (historical/observational). Funder/conflicts not stated in the abstract. Observational association only. Health Sci Rep 2026;9:e72025. Study type: controlled study.
